Bio-Path Shares Are Trading Higher After the Company Outlined Growing Evidence That Supports the Development of BP1001-A for the Treatment for Obestity and Related Metabolic Disease in Type 2 Diabetes Patients.
Bio-Path Shares Are Trading Higher After the Company Outlined Growing Evidence That Supports the Development of BP1001-A for the Treatment for Obestity and Related Metabolic Disease in Type 2 Diabetes Patients.
Bio-Path公司的股票在公司阐述了越来越多的证据支持开发BP1001-A用于治疗2型糖尿病患者的肥胖及相关代谢疾病后，交易价格上涨。
Bio-Path Shares Are Trading Higher After the Company Outlined Growing Evidence That Supports the Development of BP1001-A for the Treatment for Obestity and Related Metabolic Disease in Type 2 Diabetes Patients.
Bio-Path公司的股票在公司阐述了越来越多的证据支持开发BP1001-A用于治疗2型糖尿病患者的肥胖及相关代谢疾病后，交易价格上涨。
资讯热榜
更新时间